A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.

NCT02040584 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Transplant

Interventions

DRUG: Minimisation of TAC
DRUG: TAC + MMF + corticosteroids

Sponsor

Novartis Pharmaceuticals